Bryan Gilburg - China

“Manufacturers wishing to submit under the current Russian regulations need to expedite their applications to meet the January 1, 2022 deadline.”

Bryan Gilburg
Managing Director
Asia Actual

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Russia and Euro-Asian Neighbors Expected to Transition to EAEU Regulations in 2022

Published on: June 28th, 2021

Updated on: February 2nd, 2022

Implementation Update

Implementation has been delayed by 1 year to January 1, 2023. Manufacturers are able to still submit under Russia’s national regulations until May/June 2022. 

Regulations are Currently Expected to Take Effect at the End of the Year

With the release of Decree 142, the Russian government has provided a roadmap for their transition to the new EAEU medical device regulations beginning January 1, 2022. After this date, all applications submitted must adhere to the EAEU rules which can vary significantly from the current Russian requirements. To date, only 4 medical devices have been registered under EAEU rules even though 5 countries (Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Russia) are members. Manufacturers wishing to submit under the current Russian regulations need to expedite their applications to meet the January 1, 2022 deadline. While some might consider the delay as a sign that the implementation will be delayed, manufacturers should be cautioned Russia’s Roszdravnadzor, or RZN, have swiftly implemented new regulations before.

Seeking Registration in 2021

At this time, due to the uncertainty surrounding the actual implementation date, some manufacturers may need to enter a holding pattern for the next couple of months until more information is announced. If implemented as planned, all Russia applications submitted before December 31, 2021, will be accepted under the current regulations and granted a 5-year validity. However, if manufacturers cannot submit before the end of the year and the implementation date isn’t postponed, much of the work completed won’t be compatible under the new EAEU regulations. Therefore, manufacturers of high-risk devices may not want to begin applications until further guidance is provided. Low risk devices, on the other hand, may still be able to submit their applications before the potential deadline as application compilation and testing time is significantly reduced.

How the EAEU Regulations are Different

The EAEU regulations are set to expand QMS and clinical trial requirements for international manufacturers. Class IIa sterile, Class IIb, or Class 3 will now need to have an onsite inspection rather than using a legalized ISO 13485 certificate, as was allowed under previous Russian requirements. Additionally, the EAEU regulations will now require international manufacturers conducting multi-center trials to have one of their sites in an EEU member country in order to be registered. Previously, manufacturers could avoid clinical trials by demonstrating evidence of a predicate product already approved and on the market.

Transition Details

According to EAEU regulations, registration certificates issued according to national registration procedures of member states will be valid until terms of their validity in accordance with the national rules. Originally, under Decree 1416, Russian registration certificates were originally expected to be grandfathered into the new system and never expire. However, additional guidance has been released stating that all registrations, including those approved by Russia, will need to register under the new system by December 31, 2026. To date, only 5 products have been approved under the EAEU regulations and listed on the public database. Four of the devices are manufactured by Russian companies while the fifth is from Belarus.

Grow With Us

Asia Actual is available to help navigate the complex medical device registration requirements and regulatory pathway for medical device and IVD distribution in Russia.

Contact Asia Actual for a free consultation to discuss how these changes may affect your business.

Blog Posts

CDSCO Issues Updates to IVD Classification List in India

The Central Drugs Standard Control Organisation (CDSCO) of India issued a notice (PDF) on October 25, 2023 classifying in-vitro diagnostic (IVD) medical devices under medical device rules. The updates to IVD classification in India include intended use, associated risk, and other parameters.

Embracing Innovation and Collaboration: Highlights from the 15th CII Global MedTech Summit

On October 6, 2023, a team of enthusiastic members from the AAI (Artificial Intelligence and Innovation) group, including Ashoniya Puri, Sanjay Singh, and Rajat Budhori, had the honor of attending the prestigious 15th CII Global MedTech Summit. Hosted by the Confederation of Indian Industry (CII), one of India's largest industry bodies, this event brought together key players in the MedTech sector, both from India and abroad. The summit revolved around the central theme, "Paving the way for a USD 50 billion MedTech Industry by 2030," signifying a collective vision for the industry's future growth.


On September 18, 2023, The Directorate General of Drug Administration (DGDA) published the Drug and Cosmetics Act 2023 formalizing the regulatory requirements of medical and diagnostic devices in Bangladesh with immediate effect.  A translated version of the document is available on Asia Actual’s website here.  All medical devices now require a Marketing Authorization Certificate to clear Customs and be sold on the market in Bangladesh.